News
Press release
News
24/04/2025
Debiopharm and Oncodesign Services Launch Strategic Collaboration
Debiopharm and Oncodesign Services announce the execution of a license agreement for the use of the AbYlink technology
Press release
31/03/2025
Oncodesign Services appoints Aidan Synnott as CEO to enhance strategic drug discovery partnerships
Oncodesign Services has appointed Dr. Aidan Synnott as chief executive officer, to help strengthen its position as a trusted partner in drug discovery.
Press release
23/01/2024
Oncodesign Services Acquires ZoBio
Acquisition of ZoBio, a Dutch CRO expert in biophysics-based small molecule drug discovery, by Oncodesign Services.
Press release
27/06/2023
Oncodesign Services announce access to ImaginAb’s CD8 ImmunoPET technology
Oncodesign Services announces the execution of a Preclinical License and Supply Agreement with ImaginAb Inc.
News
22/05/2023
Oncodesign Services and Veritas In Silico enter into business cooperation
Oncodesign Services and Veritas In Silico Inc. announced that they have entered into a Memorandum of Understanding to respond to the needs of pharmaceutical companies seeking to develop innovative small molecule drugs targeting messenger RNA.
Press release
19/10/2022
ERES IV acquires a majority stake in Oncodesign Services
ERES IV, advised by Elyan Partners, acquires a majority stake in Oncodesign Services and will file an offer on the company’s remaining shares. Find out more
Press release
30/09/2022
The General Meeting of Oncodesign authorises the allocation of OPM
Each Oncodesign shareholder will receive one OPM share for one ONCODESIGN share held
Press release
28/09/2022
Euronext Paris authorises the listing of OPM shares
Oncodesign Precision Medicine (OPM) and Oncodesign announce that Euronext Paris S.A. has authorised the admission to listing on Euronext Access + market in Paris of OPM’s ordinary shares.
Press release
26/09/2022
Servier exercises the exclusive worldwide license option of their collaboration program LRRK2
Servier and Oncodesign Precision Medicine (OPM) announce that Servier has exercised its exclusive license option for their drug candidate
Press release
22/09/2022
OPM and Servier announce a strategic collaboration to discover new therapeutic targets for pancreatic cancer treatment
Global pharmaceutical group Servier and Oncodesign Precision Medicine (OPM) announce a collaborative research agreement
Press release
01/07/2022
ONCODESIGN announces the separation of its two business lines – Service and Biotech
ONCODESIGN today announced that the Board of Directors has approved the subsidiarisation of its Biotech business.
Press release
24/02/2022
Abzena, Alira Health and Oncodesign launch DRIVE-Biologics to support access to specialist services
Abzena x Alira Health x Oncodesign: unveil unique integrated solution with specialist services, from biologics discovery to clinical & commercial manufacturing